Gene In

GeneIn was a South Korean biotechnology company that specialized in the development of non-viral gene therapy delivery systems. The company's core technology, GeneIn-P, utilized a proprietary polymeric carrier designed to overcome the safety and efficiency limitations typically associated with viral vectors. GeneIn's pipeline primarily focused on oncology and cardiovascular indications, with its lead program, GeneIn-p53, reaching Phase 1/2 clinical trials for the treatment of superficial bladder cancer. By leveraging its biocompatible delivery platform, the company aimed to provide safer and more effective genetic medicines for hard-to-treat diseases, though it has been largely inactive in recent years.